Abnormal Methylation Enzymes as the Most Critical Issue of Cancer
Published: 2023-08-22
Page: 168-176
Issue: 2023 - Volume 6 [Issue 2]
Ming C. Liau *
CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.
Cristine L. Craig
CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.
Linda L. Liau
CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.
*Author to whom correspondence should be addressed.
Abstract
The objective of this study is to present convincing evidence to show that abnormal methylation enzymes (MEs) are the most critical issue of cancer, and to call for the acceptance of cell differentiation agent (CDA) formulations as the right medicines for cancer therapy. CDA formulations are the creation of the nature to function as allosteric regulators to keep abnormal MEs under control. Cancer is a disease caused by multiple factors. Toxic insults inducing cachexia symptoms to trigger a cascade of events resulting in the collapse of chemo-surveillance, which is an important allosteric mechanism to prevent the build up of cells with abnormal MEs; evolution of cancer stem cells (CSCs) from progenitor stem cells (PSCs) due to wound unhealing; and the activation of oncogenes and/or the inactivation of suppressor genes to play important roles to cause cancer. Among these multiple factors, abnormal MEs are the most critical issue of cancer. MEs play an important role on the regulation of cell replication and differentiation. This biological role is so important, so that MEs are subject to double allosteric regulations, one at the individual enzyme level and another at the enzyme complex level. When MEs become abnormal, cells are locked in perpetual state of proliferation which is the most outstanding feature of cancer. The solution of perpetual proliferation of cancer cells (CCs) is a very important issue of cancer. Killing of replicating cells and induction of terminal differentiation of replicating cells are two options to stop perpetual proliferations. The strategy based on killing of replicating cells displays the features as anti-wound healing and contra-indication of cancer therapy, whereas the strategy based on the induction of terminal differentiation displays the features as pro-wound healing and the right indication of cancer therapy. Evidently, the pro-wound healing strategy is the right approach of cancer therapy. A right approach is a golden rule to dictate the success to solve difficult challenges. Destabilization of abnormal MEs is the critical mechanism to achieve terminal differentiation of cells with abnormal MEs. Since abnormal MEs are most critical issue of cancer, the solution of cancer is best achieved by CDA formulations, the creation of the nature on allosteric regulation to take care of the issue of abnormal MEs.
Keywords: Allosteric regulation, cancer therapy, CSCs, MEs, PSCs, wound healing
How to Cite
Downloads
References
Liau MC, Fruehauf JP. Cancer moonshot: Moonshot as a magic code to guide successful solutions of tough challenges such as cancer. Intl J Res Oncol. 2023; 2(1):1-5.
Google search on cancer statistics-NCI.
Liau MC, Craig CL, Baker LL. CDA formulations to fulfill cancer moonshot and to win the war on cancer. Int J Res Oncol. 2023;2(2):1-8.
Liau MC, Fruehauf JP. It has been half a century since President Nixon declared war on cancer: Destabilization of abnormal methylation enzymes has the blessing of the nature to win the war on cancer. Adv Complement Alt Med. 2020;6(1):538-539.
Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Intl Res J Oncol. 2022;6(3):8-20.
Liau MC, Fruehauf JP. Think hard on the destabilization of abnormal methylation enzymes to combat cancer: It can be life saving. Adv Complement Alt Med. 2019; 5(3):464-465.
Liau MC, Baker LL.. Cancer patients’ lives matter. Adv Complement. Alt Med. 2021: 638-640.
Liau MC, Craig CL, Baker LL. A drastic change of cancer leaderships to save cancer patients. In: Gurunathan R, (ed.), New Advances in Medicine and Medical Science. 2023;7:61-69.
Liau MC, Craig CL. On the mechanism of wound healing and the impact of wound on cancer evolution and cancer therapy. Intl Res J Oncol. 5(3):25-31.
Liau MC. Abnormal methylation enzymes: A selective molecular target for differentiation therapy of cancer. Chin Pharm J. 2004;56(2):57-67.
Liau MC, Chang CF, Saunders GF, Tsai YH. S-Adenosylhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys. 1981;208(1):262-272.
Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Clin Oncol Cancer Res. 2010;7(2):86-96.
Liau MC, Szopa M, Burzynski B, Burszynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drugs Exptl Clin Res. 1989;13(Supple. 1):72-82.
Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012-1027.
Ma L, Li C, Yin H, Huang J, Yu S, Zhao J, et al. The mechanism of DNA methylation and miRNA in breast cancer. Intl J Mol Sci. 2023;24(11):9360.
Racanelli AC, Turner FB, Xie LY, Taylor SM, Moran RG. A mouse gene that coordinate epigenetic controls and transcriptional interference to achieve tissue specific expression. Mol Cell Biol. 2008;28(2):836-848.
Liau MC, Hunt ME, Hurlbert RB. Role of ribosomal RNA methylases in the regulation of ribosome production. Biochemistry. 1975;15(14):3158-3164.
Bernsteine KA, Bleichert F, Bean JM, Cross FR, Baserga SJ. Ribosome biogenesis is sensed at the start cell cycle check point. Mol Biol Cell. 2007;18(3):953-964.
Justilien Y, Ali SA, Jamieson L, Yin N, Cox AD, Der CJ, et al. ECT2-dependent rRNA synthesis is required for KRAS-TRP53-driven lung adenocarcinoma. Cancer Cell. 2017;31(2):256-269.
Prudova A, Bauman Z, Braun A, Vitvitsky V, Lu SV, Banerjee R. S-Adenosylmethionine stabilize cystathionine beta-synthase and modulates redox capacity. Proc Natl Acad Sci USA. 2006; 103(17):6489-6494.
Chiba P, Wallner C, Kaizer E. S-Adenosylmethionine metabolism in HL-60 cells: Effect of cell cycle and differentiation. Biochim Biophys Acta. 1988;971(1):38-45.
Liau MC, Lee SS, Burzynski SR. Hypomethylaion of nucleic acids: A key to the induction of terminal differentiation. Intl J Exptl Clin Chemother. 1989;2:187-199.
Shen L, Sing CX, He C, Zhang Y. Mechanism and function of oxidation reversal of DNA and RNA methylation. Annu Rev Biochem. 2014;83:585- 614.
Wu X, Zhang Y. TET-mediated active DNA demethylation mechanism, function and beyond. Nat Rev Genet. 2017;18(9):517-534.
Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Nov Res Sci. 2021;7(2):1-3.
Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of woun healing to avoid cancer evolution and to cure cancer. In: New Horizons in Medicine and Medical Research. 2022;6(Chapter 3):Print ISBN: 978-93-5547-607-4.
Liau MC, Baker LL. The impact of COVID-19 pandemic on cancer patients. Intl Res J Oncol. 2022;6(4):13-17.
Ho ATV, Palla AR, Blame MR, Yual ND, Wang YX, Magnusson KEG, et al. Prostaglandin E2 is essential for efficacious skeletal muscle stem functon, augmenting regeneration and strength. Proc Natl Acad Sci USA. 2017;114(26): 6675-6684.
Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof. US Patent 7232578 B2; 2007.
Kamparath BN, Liau MC, Burzynski B. Burzynski SR. Chemoprevention by Antineoplaston A10 of benzo-alpha-pyrene-induced pulmonary neoplasis. Drug Exptl Clin Res. 1987;13(Suppl. 1):51-55.
Kamparath BN, Liau MC, Burzynski B, Burzynski SR. Protective effect of Antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. Intl J Tiss React. 1990;12(Suppl.):43-50.
Liau MC, Chang CF, Becker FF. Alteration of S-adenosylmethionine synthetases during chemical hepatocarcinogenesis and in resulting carcinomas. Cancer Res. 1979; 39:2113-2119.
Williamson PJ, Kruger AR, Renolds PJ, Hamlin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndromes. Br J Haematol. 1994;87(4):743-745.
Boula A, Vougarelis M, Giannouli S, Katrinakis G, Psylalki M, Pontikoglou C, et al. Effect of CA2 of antitumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006;12(10):3099-3108.
Woll PS, Kjallquist U, Chowdburry O, Doolittle H, Wedge DC, Thongiuea S et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25(6):794-808.
Virchow R. Die Cellular Pathologie in Ihrer Begrundung auf Physiologische und Pathologische Gewebelehve. Hirschwald. 1858;16:440.
Dvorak HF. Tumors: that do not heal. N Engl J Med. 1986; 315(26):1650-1659.
MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling. 2020; 13: 648.
Liau MC, Lin GW, Hurlbert RB. Partial purification and characterization of tumor and liver S-adenosylmethionine synthetases. Cancer Res. 1977;37:427-435.
Liau MC, Chang CF, Girovanella BC. Demonstration of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Inst. 1980;64(5): 1071-1075.
Lisu MC, Craig CL. No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. J Cancer Tumor Intl. 2022;12(1):29-34.
Liau MC, Craig CL, Baker LL. Wound unhealing as a grave issue of cancer. Intl Res J Oncol. 2023;6(1):97-103.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes: Nature’s way to eradicate cancer stem cells. Online J Complement Alt Med; 2019.
DOI: 10.33552/OJCAM.2019.02.000546
Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant celllular transformation. Cancer Sci. 2012;103(4): 670-676.
Ficz GM, Gibben JG, Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence? 2014;104(5):352-357.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: The nature’s choice to win the war on cancer. Lambert Academic Publishing. 2020;978-620-2-66889-7.
Liau MC, Baker LL. Destruction promotes the proliferation of progenitor stem cells and cancer stem cells. Therefore, non-destruction is a better strategy for cancer therapy. J Pharmacol Pharmaceu Pharmacovigi. 2020;4:029.
DOI: 10.24966/PPP-5649/100029
Liau MC, Craig CL. Baker LL. Wound healing process as the most appropriate modality of cancer therapy. Eur J Applied Sci. 2023;11(1):463-471.
Santi DV, Norment A, Garret CE. Covalent bond formation between a DNA-cytosine methyltransferase of DNA containing 5-azacytosine. Proc Natl Acad Sci USA. 1984;81(22):6993-6997.
Prassana P, Shack S, Wilson VL, Samid D. Phenylacetate in chemoprevention of 5-aza-2’-deoxycytidine-induced carcinogenesis. Clin Cancer Res. 1995; 1(18):865-871.
Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, DausmanJ, Gray JW, et al. Induction of tumor in mice by genomic hypomethylation. Science. 2003; 300(5816):489-492.
Palii SS, van Emburg BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-aza-2’-deoxycytidine induces reversible DNA damage that is distinctly influenced by DNA-methytransferase 1 and 3B. Mol Cell Biol. 2008; 28(2):752-771.
Kizietepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, et al. 5-Azacytidine, a methyltransferase inhibitor, induces ATR-mediated DNA-double strand break responses, apoptosis, and synergistic cytototoxicity with doxorubicine and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6(6):1718-1727.
Yang Q, Wu F, Wang F, Cai K, Zhang Y, Sun Q, et al. Impact of DNA methyltransferase inhibitor 5-azacytidine on cardiac development of zebrafish in vivo and cardiomyocyte proliferation, apoptosis, and the homeostasis of gene expression in vitro. J Cell Biochem. 2019; 120(10):17459- 17471.
Liau MC, Baker LL, Abnormal methylation enzymes as the bullseye of targeted cancer therapy. Nov Res Sci. 2021;7(4): 1-3.
Liau MC, Fruehauf JP. Winning formulas to fulfill cancer moonshot. Intl J Res Oncol. 2022;1(1):1-5.
Liau MC, Craig CL, Baker LL. CDA formulations to fulfill cancer moonshot and to win the war on cancer. Intl J Res Oncol. 2023;2(2):1-8.